The successful completion of patient enrollment in the Phase IIb study of pirepemat marks a significant milestone in its development. Pirepemat is being investigated for its potential to reduce the number of falls in individuals with Parkinson's disease. Kristina Torfgård, CEO of IRLAB, expressed optimism about moving forward to complete the study and prepare for Phase III.
Initial measurements indicate that participants fall 2-3 times more than expected at baseline. However, blinded data from the study suggest a reduction in falls by about one-third compared to the baseline period. It's important to note that, due to the double-blind nature of the study, the specific effects of pirepemat versus placebo cannot yet be determined. A clinically meaningful difference in fall frequency reduction is estimated at about 25% compared to placebo.
Falls represent a significant challenge in Parkinson's disease, impacting quality of life and causing injuries. Participants in the study have reported high satisfaction during the treatment period. Joakim Tedroff, Chief Medical Officer at IRLAB, highlighted the observed reduction in fall rates as an interesting development, despite the study's double-blind status. The focus now shifts to completing the participation of patients still under treatment in the study.
